Waters Launches Columns Designed for Faster GLP-1 Peptide Analysis
Saturday, June 20th, 2026 - Waters Corporation has introduced new reversed-phase liquid chromatography columns specifically engineered to accelerate analysis of GLP-1 peptide drugs and lipid nanoparticles, the company announced. The new columns aim to reduce run times for quality control testing of peptide therapeutics including semaglutide, tirzepatide, and related compounds, according to the manufacturer's product release.
The columns are designed for pharmaceutical manufacturers conducting purity and stability testing on GLP-1-based drugs, which have seen surging production volumes. Waters said the technology also supports analysis of lipid nanoparticles used in mRNA and peptide delivery systems.
Regulatory Concerns Over Unapproved Peptide Products
Australia's Therapeutic Goods Administration (TGA) issued a warning about unapproved peptide products circulating in the market, according to a separate advisory. The regulator raised concerns about products being sold without marketing authorization, noting that such products have not been evaluated for quality, safety, or efficacy.
The TGA warning follows reports of serious adverse events linked to counterfeit peptide drugs. Australian media outlets reported that six people were hospitalized, including a Melbourne woman who suffered acute liver failure after using a product labeled as the peptide compound retatrutide purchased from a beautician.
Research Identifies Rice Peptide for Gastric Protection
A study published in Nature's npj Science of Food identified a rice bran protein peptide, designated PVLWGVPKG (PV9), that reduced Helicobacter pylori adhesion to gastric epithelial cells. Molecular docking analysis suggested the peptide and its degradation fragments could bind to H. pylori adhesion factors, potentially offering a dietary approach to mitigate gastric mucosal damage from infection.
